A decade’s studies on metastasis of hepatocellular carcinoma

  • Zhao-You Tang
  • Sheng-Long Ye
  • Yin-Kun Liu
  • Lun-Xiu Qin
  • Hui-Chuan Sun
  • Qin-Hai Ye
  • Lu Wang
  • Jian Zhou
  • Shuang-Jian Qiu
  • Yan Li
  • Xue-Ning Ji
  • Hu Liu
  • Jing-Ling Xia
  • Zhi-Quan Wu
  • Jia Fan
  • Zeng-Chen Ma
  • Xin-Da Zhou
  • Zhi-Ying Lin
  • Kang-Da Liu
Review

Abstract

Metastasis remains one of the major challenges before hepatocellular carcinoma (HCC) is finally conquered. This paper summarized a decade’s studies on HCC metastasis at the Liver Cancer Institute of Fudan University. We have established a stepwise metastatic human HCC model system, which included a metastatic HCC model in nude mice (LCI-D20), a HCC cell line with high metastatic potential (MHCC97), a relatively low metastatic potential cell clone (MHCC97L) and several stepwise high metastatic potential cell clones (MHCC97H, HCCLM3, and HCCLM6) from their parent MHCC97 cell. Endeavors have been made for searching human HCC metastasis-related chromosomes/proteins/genes. Monogene-based studies revealed that HCC invasion/metastasis was similar to that of other solid tumors, and the biological characteristics of small HCC were only slightly better than that of large HCC. Using comparative genomic hybridization (CGH), fluorescence in situ hybridization (FISH), genotyping, cDNA microarray, and 2-dimensional gel electrophoresis, we obtained some interesting results. In particular, in collaboration with the National Institute of Health (NIH) in the United States, we generated a molecular signature that can classify metastatic HCC patients, identified osteopontin as a lead gene in the signature, and found that genes favoring metastasis progression were initiated in the primary tumors. We also found that chromosome 8p deletion, particularly in the region of 8p23, was associated with HCC metastasis. Cytokeratin 19 was identified as one of the proteins, which was found in MHCC97H, but not in MHCC97L cells. Experimental interventions using the high metastatic nude mice model have provided clues for the prevention of HCC metastasis. Translation from workbench to bedside demonstrated that serum VEGF, microvessel density, and p53 scoring may be of value for the prediction of postoperative metastatic recurrence. Interferon alpha proved effective for the prevention of recurrence both experimentally and clinically. In conclusion, HCC metastasis that probably initiated in the primary tumor is a multigene-involved, multistep, and changing process. The further elucidation of the mechanism underlying HCC metastasis will provide a more solid basis for the prediction and prevention of the metastatic recurrence of HCC.

Keywords

Hepatocellular carcinoma Metastasis Prediction of metastasis Experimental intervention cDNA microarray Proteomics 

References

  1. Aruga A, Takasaki K, Hanyu F (1993) Establishment and characterization of liver metastatic model of human hepatoma in nude mice. Int Hepatol Commun 1:138–145Google Scholar
  2. Bu W, Huang XW, Tang ZY (1997) The role of MMP-2 in the invasion and metastasis of hepatocellular carcinoma. Zhonghua Yixue Zazhi (Natl Med J China) 77:661–664 (Chin)Google Scholar
  3. Bu W, Tang ZY, Sun FX, Ye SL, Liu KD, Xue Q, Chen J, Gao DM (1998) Effects of matrix metalloproteinase inhibitor BB-94 on liver cancer growth and metastasis in a patient-like orthotopic model LCI-D20. Hepato-Gastroenterol 45:1056–1061Google Scholar
  4. Clark EA, Golub TR, Lander ES, et al (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406:532–535PubMedGoogle Scholar
  5. Collonge-Rame MA, Bresson-Hadni S, Koch S, Carbillet JP, Blagosklonova O, Mantion G, Miguet JP, Heyd B, Bresson JL (2001) Pattern of chromosomal imbalances in non-B virus related hepatocellular carcinoma detected by comparative genomic hybridization. Cancer Genet Cytogenet 127:49–52CrossRefPubMedGoogle Scholar
  6. Eisenhauer EA (2003) From the molecule to the clinic- Inhibiting HER2 to treat breast cancer (editorial) N Engl J Med 344:841–842Google Scholar
  7. He B, Tang ZY, Liu KD, Zhou G (1996) Analysis of the cellular origin of hepatocellular carcinoma by p53 genotype. J Cancer Res Clin Oncol 122:763–766PubMedGoogle Scholar
  8. He B, Liu YK, Tang ZY, Xue Q (1997) Gene mutation and expression in metastatic model of human hepatocellular carcinoma in nude mice established by orthotopic implantation. Zhonghua Ganzangbing Zazhi (Chin J Hepatol) 5:245–245 (Chin)Google Scholar
  9. Ijichi M, Takayama T, Matsumura M, Shiratori Y, Omata M, Makuuchi M (2002) alpha-Fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: a prospective study. Hepatology 35:853–860CrossRefPubMedGoogle Scholar
  10. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H (2000) Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32:228–232PubMedGoogle Scholar
  11. Jemal A, Thomas A, Murray T, Thum M (2002) Cancer statistics, 2002. CA Cancer J Clin 52:23–47PubMedGoogle Scholar
  12. Ji XN, Ye SL, Li Y, Tian B, Chen J, Gao DM, Bao WH, Liu YK, Tang ZY (2003) Contribution of lung tissue extracts to invasion and migration of human hepatocellular carcinoma cells with various metastatic potentials. J Cancer Res Clin Oncol 129:556–564Google Scholar
  13. Jiang XP, Liu KD, Zhou XD, Tang ZY, Zhang ZF, Zhang Y, Wu XF (1994) Identification of a new human nm23 gene, nm 23-H3b. Chin J Cancer Res 6:18–23Google Scholar
  14. Jin F, Xiang YB, Gao YT (1998) Cancer survival in Shanghai, People’s Republic of China. In: Sankaranaryanan R, Black RJ, Parkin DM (eds) Cancer survival in developing countries. IARC Scientific Publication No. 145. IARC, Lyon, pp. 37–50Google Scholar
  15. Jinno K, Tanimizu M, Hyodo I, Nishikawa Y, Hosokawa Y, Doi T, Endo H, Yamashita T, Okada Y (1998a) Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma. J Gastroenterol 33:376–382CrossRefPubMedGoogle Scholar
  16. Jinno K, Tanimizu M, Hyodo I, Nishikawa Y, Hosokawa Y, Endo H, Doi T, Mandai K, Ishitsuka H (1998b) Circulating platelet-derived endothelial cell growth factor increases in hepatocellular carcinoma patients. Cancer 82:1260–1267CrossRefPubMedGoogle Scholar
  17. Kim J, Kim SH, Lee SU, Ha GH, Kang DG, Ha NY, Ahn JS, Cho HY, Kang SJ, Lee YJ, Hong SC, Ha WS, Bae JM, Lee CW, Kim JW (2002) Proteome analysis of human liver tumor tissue by two-dimensional gel electrophoresis and matrixassisted laser desorption/ionization-mass spectrometry for identification of disease-related proteins. Electrophoresis 23:4142–4156CrossRefPubMedGoogle Scholar
  18. Kitay-Cohen Y, Amiel A, Ashur Y, Fejgin MD, Herishanu Y, Afanasyev F, Bomstein Y, Lishner M (2001) Analysis of chromosomal aberrations in large hepatocellular carcinomas by comparative genomic hybridization. Cancer Genet Cytogenet 131:60–64CrossRefPubMedGoogle Scholar
  19. Kobayashi T, Kubota K, Takayama T, Makuuchi M (2001) Telomerase activity as a predictive marker for recurrence of hepatocellular carcinoma after hepatectomy. Am J Surg 181:284–288CrossRefPubMedGoogle Scholar
  20. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H (2002) Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 89:418–422CrossRefPubMedGoogle Scholar
  21. Kusano N, Okita K, Shirahashi H, Harada T, Shiraishi K, Oga A, Kawauchi S, Furuya T, Sasaki K (2002) Chromosomal imbalances detected by comparative genomic hybridization are associated with outcome of patients with hepatocellular carcinoma. Cancer 94:746–751CrossRefPubMedGoogle Scholar
  22. Lau WY, Leung TW, Ho SK, Chan M, Machin D, Lau J, Chan AT, Yeo W, Mok TS, Yu SC, Leung NW, Johnson PJ (1999) Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 353:797–801PubMedGoogle Scholar
  23. Li XM, Tang ZY, Zhou G, Liu YK, Ye SL (1998a) Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 17:13–17PubMedGoogle Scholar
  24. Li XM, Tang ZY, Xue Q, Liu YK, Ye SL, Zhang XR, Zhao ZH (1998b) Suramin inhibits growth and metastasis of human hepatocellular cacinoma in nude mice. Zhonghua Shiyan Waike Zazhi (Chin J Exp Surg) 15:3–4 (Chin)Google Scholar
  25. Li XM, Tang ZY, Chen FG (1998c) Gene transfer of dominant-negative flk-1 mutant inhibits angiogenesis, growth and metastases of human hepatocellular carcinoma in nude mice. Zhongguo Zhongliu Shengwu Zhiliao Zazhi (Chin J Cancer Biother) 5:160–162 (Chin)Google Scholar
  26. Li XM, Sun HC, Tang ZY, Zhou J (1999a) Cytostatic calcium influx inhibitor carboxyamido- triazole inhibited angiogenesis induced by human hepatocellular carcinoma. Zhonghua Shiyan Waike Zazhi (Chin J Exp Surg) 16:489–490 (Chin)Google Scholar
  27. Li XM, Tang ZY, Qin LX, Zhou J, Sun HC (1999b) Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellula rcarcinoma. J Exp Clin Cancer Res 18:511–517PubMedGoogle Scholar
  28. Li Y, Tang ZY, Ye SL, Liu YK, Chen J, Xue Q, Chen J, Gao DM, Bao WH (2001) Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol 7:630–636PubMedGoogle Scholar
  29. Li Y, Tang ZY, Ye SL, Liu BB, Liu YK, Chen J, Xue Q (2003) Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray. J Cancer Res Clin Oncol 129:43–51PubMedGoogle Scholar
  30. Liang XH, Loncarevic IF, Tang ZY, Yu YQ, Zentgraf H, Schroder CH (1991) Resection of hepatocellular carcinoma: Oligocentric origin of recurrent and multinodular tumours. J Gastroenterol Hepatol 6:77–80PubMedGoogle Scholar
  31. Liao Y, Tang ZY, Ye SL, Liu KD, Sun FX, Huang Z (2000) Modulation of apoptosis, tumorigenesity and metastatic potential with antisense H-ras oligodeoxynucleotides in a high metastatic tumor model of hepatoma: LCI-D20. Hepatogastroenterology 47:365–370Google Scholar
  32. Liu H, Ye SL, Yang J, Tang ZY, Liu YK, Qin LX, Qiu SJ, Sun RX (2002) The microcell mediated transfer of human chromosome 8 into highly metastatic rat liver cancer cell line C5F. World J Gastroenterol 9:449–453Google Scholar
  33. Liu H, Ye SL, Li WC, LiY, Liu YK, Qin LX, Qiu SJ, Sun RX, Chen J, Tang ZY (2003) Quantitative analysis of expression of TEY1 gene in liver cancer cells with different metastatic potential. Ai Zheng (Chin J Cancer) 22:561–565 (Chin)Google Scholar
  34. Liu YK, Li Y, Ma XM, Chen J, Xue Q, Gao DM, Zhang Y, Ye SL, Tang ZY (2002) Regulation of liver cancer related gene and alpha fetal protein expression by cell differentiation agent II. Zhongguo Zhongliu 11:169–172 (Chin)Google Scholar
  35. Mou DC, Cai SL, Peng JR, Wang Y, Chen HS, Pang XW, Leng XS, Chen WF (2002) Evaluation of MAGE-1 and MAGE-3 as tumour-specific markers to detect blood dissemination of hepatocellular carcinoma cells. Br J Cancer 86:110–116CrossRefPubMedGoogle Scholar
  36. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50–56PubMedGoogle Scholar
  37. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E, Nakamura T, Kojima T (1996) Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 334:1561–1567CrossRefPubMedGoogle Scholar
  38. Muto Y, Moriwaki H, Saito A (1999) Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 340:1046–1047CrossRefPubMedGoogle Scholar
  39. Niu Q, Tang ZY, Ma ZC, Qin LX, Zhang LH (2000a) Serum vascular endothelial growth factor is a potential biomarker of metastatic recurrence after curative resection of hepatocellular carcinoma. World J Gastroenterol 6:565–568PubMedGoogle Scholar
  40. Niu Q, Tang ZY, Chen L, Ma ZC, Qin LX, Zhang LH (2000b) Basic fibroblast growth factor is a potential predictive marker of metastatic recurrence after resection of hepatocellular carcinoma. Zhonghua Waike Zazhi (Chin J Surg) 38:637–639 (Chin)Google Scholar
  41. Niu Q, Tang ZY, Ma ZC, Qin LX, Bao WH, Zhang LH (2001) Relationship between serum matrix metalloproteinase-2 and metastasis and recurrence following radical hepatic resection in hepatocellular carcinoma. Zhonghua Ganzangbing Zazhi (Chin J Hepatol) 9:56–58 (Chin)Google Scholar
  42. Okochi O, Hibi K, Uemura T, Inoue S, Takeda S, Kaneko T, Nakao A (2002) Detection of mitochondrial DNA alterations in the serum of hepatocellular carcinoma patients. Clin Cancer Res 8:2875–2878PubMedGoogle Scholar
  43. Ono T, Yamanoi A, Nazmy El Assal O, Kohno H, Nagasue N (2001) Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: meta-analysis of three randomized controlled trials. Cancer 91:2378–2385CrossRefPubMedGoogle Scholar
  44. Pan H-W, Ou Y-H, Peng S-Y, Liu S-H, Lai P-L, Lee P-H, Sheu J-C, Chen C-L, Hsu H-C (2003) Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98:119–127CrossRefPubMedGoogle Scholar
  45. Parasole R, Izzo F, Perrone F, Pignata S, Galati MG, Leonardi E, Castiglione F, Orlando R, Castello G, Esposito G, Gallo C, Daniele B (2001) Prognostic value of serum biological markers in patients with hepatocellular carcinoma. Clin Cancer Res 7:3504–3509PubMedGoogle Scholar
  46. Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimsating the world cancer burden: globocan 2000. Int J Cancer 94:153–156CrossRefPubMedGoogle Scholar
  47. Poon RT, Ng IO, Lau C, Zhu LX, Yu WC, Lo CM, Fan ST, Wong J (2001a) Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 233:227–235CrossRefPubMedGoogle Scholar
  48. Poon RT, Ng IO, Lau C, Yu WC, Fan ST, Wong J (2001b) Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg 182:298–304CrossRefPubMedGoogle Scholar
  49. Qin LX, Tang ZY, Liu KD, Ye SL, Zhou G (1995) p53 mutations may be related to tumor invasiveness of human hepatocellular carcinoma in China. Oncol Rep 2:1175–1179Google Scholar
  50. Qin LX, Tang ZY, Liu KD, Ye SL, He B, Zhang Y, Zhou G (1996) Alterations of CDKN2 (P16/MTS1) exon 2 in human hepatocellular carcinoma. Oncol Rep 3:405–408Google Scholar
  51. Qin LX, Tang ZY, Sham JST, Ma ZC, Ye SL, Zhou XD, Wu ZQ, Trent JM, Guan XY (1999) The association of chromosome 8p deletion and tumor metastasis in human hepatocellular carcinoma. Cancer Res 59:5662–5665PubMedGoogle Scholar
  52. Qin LX, Tang ZY, Ye SL, Liu YK, Ma ZC, Zhou XD, Wu ZQ, Lin ZY, Sun FX, Tian J, Guan X-Y, Pack SD, Zhuang ZP (2001) Chromosome 8p deletion is associate with metastasis of human hepatocellular carcinoma when high and low metastatic models are compared. J Cancer Res Clin Oncol 127:482–488Google Scholar
  53. Qin LX, Tang ZY, Ma ZC, Wu ZQ, Zhou XD, Ye QH, Yuan J, Huang LW, Jia HL, Sun HC, Wang L (2002a) P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection. World J Gastroenterol 8:459–463PubMedGoogle Scholar
  54. Qin LX, Tang ZY (2002b) The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 8:385–392PubMedGoogle Scholar
  55. Qiu SJ, Ye SL, Wu ZQ, Tang ZY, Liu YK (1998) The expression of the mdm2 gene may be related to the aberration of the p53 gene in human hepatocellular carcinoma. J Cancer Res Clin Oncol 124:253–258CrossRefPubMedGoogle Scholar
  56. Saffroy R, Lelong JC, Azoulay D, Salvucci M, Reynes M, Bismuth H, Debuire B, Lemoine A (1999) Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. Br J Cancer 79:604–610CrossRefPubMedGoogle Scholar
  57. Schwartz JD, Schwartz M, Mandeli J, Sung M (2002) Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 3:593–603CrossRefPubMedGoogle Scholar
  58. Seki S, Kitada T, Kawada N, Sakaguchi H, Kadoya H, Nakatani K, Satake K, Kuroki T (1999) Establishment and characteristics of human hepatocellular carcinoma cells with metastasis to lymph nodes. Hepatogastroenterology 46:2812–2817PubMedGoogle Scholar
  59. Seow TK, Liang RC, Leow CK, Chung MC (2001) Hepatocellular carcinoma: from bedside to proteomics. Proteomics 1:1249–1263CrossRefPubMedGoogle Scholar
  60. Shao DM, Wang QH, Chen C, Shen ZH, Yao M, Zhou XD, Tang ZY, Gu JX (1999) N-Actylglucosaminyltransferase V activity in metastatic models of human hepatocellular carcinoma in nude mice. J Exp Clin Cancer Res 18:331–335PubMedGoogle Scholar
  61. Steeg PS (2003) Angiogenesis inhibitors: motivator of metastasis? Nature Med 9:822–823CrossRefPubMedGoogle Scholar
  62. Sun FX, Tang ZY, Liu KD, Ye SL, Xue Q, Gao DM, Ma ZC (1996) Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. Int J Cancer 66:239–243CrossRefPubMedGoogle Scholar
  63. Sun HC, Tang ZY, Zhou G, Li XM (1998) Kai-1 gene expression in hepatocellular carcinoma and its relationship with intrahepatic metastases. J Exp Clin Cancer Res 17:307–311PubMedGoogle Scholar
  64. Sun HC, Li XM, Xue Q, Chen J, Gao DM, Tang ZY (1999a) Study of angiogenesis induced by metastatic and non-metastatic liver cancer by corneal micropocket model in nude mice. World J Gastroenterol 5:116–118PubMedGoogle Scholar
  65. Sun HC, Zhang M, Tang ZY, Li XM, Wang L, Gao DM, Xue Q, Chen J (1999b) Inhibition of growth of LCI D20 hepatocellular carcinoma by Endostatin. Zhonghua Shiyan Waike Zazhi (Chin J Exp Surg) 116:491–492 (Chin)Google Scholar
  66. Sun HC, Tang ZY, Li XM, Zhou YN, Sun BR, Ma ZC (1999c) Microvessel density of hepatocellular carcinoma: its relationship with prognosis. J Cancer Res Clin Oncol, 125:419–426Google Scholar
  67. Sun HC, Tang ZY (2003) Preventive treatments for recurrence after curative resection of hepatocellular carcinoma—a literature review of randomized control trials. World J Gastroenterol 9:635–640PubMedGoogle Scholar
  68. Sun JJ, Zhou XD, Liu YK, Tang ZY, Feng JX, Zhou G, Xue Q, Chen J (1999) Invasion and metastasis of liver cancer: expression of intercellular adhesion molecule 1. J Cancer Res Clin Oncol 125:28–34CrossRefPubMedGoogle Scholar
  69. Sun JJ, Zhou XD, Liu YK, Tang ZY, Sun RX, Zhao Y, Uemura T (2000) Inhibitory effects of syntheticβpeptide on invasion and metastasis of liver cancer. J Cancer Res Clin Oncol 126:595–600PubMedGoogle Scholar
  70. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T (2000) Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356:802–807CrossRefPubMedGoogle Scholar
  71. Tang ZY (1989) Small hepatocellular carcinoma. In: Tang ZY, Wu MC, Xia SS (eds) Primary liver cancer. Berlin, Springer, pp. 191–203Google Scholar
  72. Tang ZY (2003) Thirty years’ studies on surgery and related basic research of hepatocellular carcinoma. Ann Coll Surg HK 7:11–17Google Scholar
  73. Tang ZY, Ma ZC (1989) Establishment of transplantable human hepatocellular carcinoma in nude mice and their use in studies of tumor markers and radioimmunodetection. In: Tang ZY Wu MC, Xia SS (eds) Primary liver cancer. Berlin, Springer, pp. 172–179Google Scholar
  74. Tang ZY, Yu YQ, Zhou XD (1984) An important approach to prolonging survival further after radical resection of AFP positive hepatocellular carcinoma. J Exp Clin Cancer Res 3:359–366Google Scholar
  75. Tang ZY, Qin LX, Wang XM, Zhou G, Liao Y, Weng Y, Jiang XP, Lin ZY, Liu KD, Ye SL (1998) Alterations of oncogenes, tumor suppressor genes and growth factors in hepatocellular carcinoma: with relation to tumor size and invasiveness. Chin Med J 111:313–318PubMedGoogle Scholar
  76. Tang ZY, Zhou XD, Lin ZY, Yang BH, Ma ZC, Ye SL, Wu ZQ, Fan J, Liu YK, Liu KD, Qin LX, Tian J, Sun HC, He B, Xia JL, Qiu SJ, Zhou J (1999) Surgical treatment of hepatocellular carcinoma and related basic research with special reference to recurrence and metastasis. Chin Med J 112:887–891PubMedGoogle Scholar
  77. Tian J, Tang ZY, Ye SL, Liu YK, Lin ZY, Chen J, Xue Q (1999) New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expression of the factors associated with metastasis. Br J Cancer 81:814–821PubMedGoogle Scholar
  78. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AAM, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton M, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards AR (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009CrossRefPubMedGoogle Scholar
  79. Wang G, Zhao Y, Liu X, Wang L, Wu C, Zhang W, Liu W, Zhang P, Cong W, Zhu Y, Zhang L, Chen S, Wan D, Zhao X, Huang W, Gu J (2001) Allelic loss and gain, but not genomic instability, as the major somatic mutation in primary hepatocellular carcinoma. Genes Chromosomes Cancer 31:221–227CrossRefPubMedGoogle Scholar
  80. Wang L, Tang ZY, Qin LX, Wu XF, Sun HC, Xue Q, Ye SL (2000a) High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology 32:43–48PubMedGoogle Scholar
  81. Wang L, Tang ZY, Xue Q, Sun HC, Chen J, Zhang XR, Zhao ZH, Gao DM, Liu YK, Ye SL (2000b) Effect of interferon-α and all-trans retinoic acid on recurrence and metastasis of hepatocellular carcinoma. Zhonghua Shiyan Waike Zazhi (Chin J Exp Surg) 17:421–423 (Chin)Google Scholar
  82. Wang XM, Tang ZY, Xue Q, Hong XY, Bao WH, Zou HQ (1995) Transforming growth factor α induces proliferation and expression of epidermal growth factor receptor in hepatocellular carcinoma cells. J Exp Clin Cancer Res 14:179–184Google Scholar
  83. Witzigmann H, Geissler F, Benedix F, Thiery J, Uhlmann D, Tannapfel A, Wittekind C, Hauss J (2002) Prospective evaluation of circulating hepatocytes by alpha-fetoprotein messenger RNA in patients with hepatocellular carcinoma. Surgery 131:34–43CrossRefPubMedGoogle Scholar
  84. Wong CM, Lee JM, Lau TC, Fan ST, Ng IO (2002) Clinicopathological significance of loss of heterozygosity on chromosome 13q in hepatocellular carcinoma. Clin Cancer Res 8:2266–2272PubMedGoogle Scholar
  85. Wong IH, Lau WY, Leung T, Yeo W, Johnson PJ (1999) Hematogenous dissemination of hepatocytes and tumor cells after surgical resection of hepatocellular carcinoma: a quantitative analysis. Clin Cancer Res 5:4021–4027PubMedGoogle Scholar
  86. Wu XF, Fan J, Lin ZY, Wu ZQ, Lu JZ, Zhou J, Tang ZY (2003) Quantitative analysis of AFP m RNA in portal, hepatic and peripheral venous blood of patients with HCC during liver surgery and its clinical significance. Zhonghua Gandan Waike Zazhi (Chin J Hepatobiliary Surg) 9:338–341 (Chin)Google Scholar
  87. Xia JL, Yang BH, Tang ZY, Sun FX, Xue Q, Gao DM (1997) Inhibitory effect of the angiogenesis inhibitor TNP-470 on tumor growth and metastasis in nude mice bearing human hepatocellular carcinoma. J Cancer Res Clin Oncol 123:383–387CrossRefPubMedGoogle Scholar
  88. Xu XR, Huang J, Xu ZG, Qian BZ, Zhu ZD, Yan Q, Cai T, Zhang X, Xiao HS, Qu J, Liu F, Huang QH, Cheng ZH, Li NG, Du JJ, Hu W, Shen KT, Lu G, Fu G, Zhong M, Xu SH, Gu WY, Huang W, Zhao XT, Hu GX, Gu JR, Chen Z, Han ZG (2001) Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci USA 98:15089–15094CrossRefPubMedGoogle Scholar
  89. Yang J, Qin LX, Ye SL, Liu YK, Li Y, Gao DM, Chen J, Tang ZY (2003) The abnormalities of chromosome 8 in two hepatocellular carcinoma cell lines with the same genetic background and different metastatic potential. J Cancer Res Clin Oncol 129:303–308PubMedGoogle Scholar
  90. Yao M, Zhou XD, Zha XL, Shi DR, Fu J, He JY, Lu HF, Tang ZY (1997) Expression of the integrin α5 subunit and its mediated cell adhesion in hepatocellular carcinoma. J Cancer Res Clin Oncol 123:435–440CrossRefPubMedGoogle Scholar
  91. Yao M, Zhou DP, Jiang SM, Wang QH, Zhou XD, Tang ZY, Gu JX (1998a) Elevated activity of N-acetylglucosaminyltransferase V in human hepatocellular carcinoma. J Cancer Res Clin Oncol 124:27–30CrossRefPubMedGoogle Scholar
  92. Yao M, Zhou XD, Liu YK, Tang ZY (1998b) Expression of E-cadherin in hepatocellular carcinoma with high invasiveness. Zhonghua Xiaohua Zazhi (Chin J Digest) 18:31–33 (Chin)Google Scholar
  93. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen YD, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY, Wang XW (2003) Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nature Med 9:416–423CrossRefPubMedGoogle Scholar
  94. Ye YJ, Yu YQ, Tang ZY, Wan DF, Lu JZ, He LP (1998) Construction of nm23-H1 cDNA clone and the relationship between its mRNA expression and metastasis in hepatocellular carcinoma. Zhonghua Shiyan Waike Zazhi (Chin J Exp Surg) 15:17–18 (Chin)Google Scholar
  95. Zhang LH, Qin LX, Ma ZC, Ye SL, Liu YK, Ye QH, Wu X, Huang W, Tang ZY (2003) Allelic imbalance regions on chromosomes 8p, 17p and 19p related to metastasis of hepatocellular carcinoma: comparison between matched primary and metastatic lesions in 22 patients by genomic microsatellite analysis. J Cancer Res Clin Oncol 129:279–286PubMedGoogle Scholar
  96. Zhao X, Li J, He Y, Lan F, Fu L, Guo J, Zhao R, Ye Y, He M, Chong W, Chen J, Zhang L, Yang N, Xu B, Wu M, Wan D, Gu J (2001) A novel growth suppressor gene on chromosome 17p13.3 with a high frequency of mutation in human hepatocellular carcinoma. Cancer Res 61:7383–7387PubMedGoogle Scholar
  97. Zhao X, He M, Wan D, Ye Y, He Y, Han L, Guo M, Huang Y, Qin W, Wang MW, Chong W, Chen J, Zhang L, Yang N, Xu B, Wu M, Zuo L, Gu J (2003) The minimum LOH region defined on chromosome 17p13.3 in human hepatocellular carcinoma with gene content analysis. Cancer Lett 190:221–232CrossRefPubMedGoogle Scholar
  98. Zheng Q, Tang ZY, Xue Q (1998a) Changes of PAI-1 and biological behaviour of human hepatocellular carcinoma in metastatic model of nude mice. Zhonghua Waike Zazhi (Chin J Surg) 36:687–689 (Chin)Google Scholar
  99. Zheng Q, Tang ZY, Xue Q (1998b) Role of heparin on tumor growth and metastasis in model of human hepatocellular carcinoma in nude mice. Zhonghua Ganzangbing Zazhi (Chin J Hepatol) 6:151–152 (Chin)Google Scholar
  100. Zheng Q, Tang ZY, Wu ZQ (1999) Changes of PAI-1 in plasma and tumor extract of patients with hepatocellular carcinoma. Zhonghua Xiaohua Zazhi (Chin J Digest) 19:16–18 (Chin)Google Scholar
  101. Zheng Q, Tang ZY, Xue Q, Shi DR, Song HY, Tang HB (2000) Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J Cancer Res Clin Oncol 126:641–646CrossRefPubMedGoogle Scholar
  102. Zheng XY, Lin ZY, Tang ZY, Liu YK, Feng XL, Zhuang W (1998) The abundance of NM23-H1 mRNA is related with in situ microenvironment and intrahepatic metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res 17:337–341PubMedGoogle Scholar
  103. Zhou J, Tang ZY, Fan J, Wu ZQ, Li XM, Liu YK, Liu F, Sun HC, Ye SL (2000a) Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus. J Cancer Res Clin Oncol 126:57–61PubMedGoogle Scholar
  104. Zhou J, Tang ZY, Fan J, Wu ZQ, Ji Y, Wang L, Bao WH, Qiu SJ (2000b) Study on inhibition of the growth and metastasis of LCID20 hepatocellular carcinoma by capecitabine. Zhonghua Shiyan Waike Zazhi (Chin J Exp Surg) 17:403–405 (Chin)Google Scholar
  105. Zhou J, Tang ZY, Fan J, Wu ZQ, Ji Y, Ye SL (2001) The potential of plasma thrombomodulin as a biomarker of portal vein tumor thrombus in hepatocellular carcinoma. J Cancer Res Clin Oncol 127:559–564CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Zhao-You Tang
    • 1
  • Sheng-Long Ye
    • 1
  • Yin-Kun Liu
    • 1
  • Lun-Xiu Qin
    • 1
  • Hui-Chuan Sun
    • 1
  • Qin-Hai Ye
    • 1
  • Lu Wang
    • 1
  • Jian Zhou
    • 1
  • Shuang-Jian Qiu
    • 1
  • Yan Li
    • 1
  • Xue-Ning Ji
    • 1
  • Hu Liu
    • 1
  • Jing-Ling Xia
    • 1
  • Zhi-Quan Wu
    • 1
  • Jia Fan
    • 1
  • Zeng-Chen Ma
    • 1
  • Xin-Da Zhou
    • 1
  • Zhi-Ying Lin
    • 1
  • Kang-Da Liu
    • 1
  1. 1.Liver Cancer InstituteZhongshan HospitalShanghaiP. R. China

Personalised recommendations